FDA OTC ocular allergy indication guidelines requested by Alcon representative.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC OCULAR ALLERGY INDICATION GUIDELINES REQUESTED by Harvard Medical School clinical associate professor for ophthalmology Mark Abelson, MD, at the Dec. 9 meeting of the FDA Ophthalmics Subcommittee. Abelson spoke on behalf of Alcon Labs, which markets Naphcon-A OTC eye drops. Abelson's presentation addressed the current situation that some OTC oral antihistamines and ocular vasoconstrictors carry the ocular allergy claim and other OTC antihistamine vasoconstrictor products, like Naphcon-A, do not.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning